Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Cantor Global Healthcare Conference September 17, 2024 9:10 AM ET Company Participants Susie Lisa - SVP, IR Manisha Pai - Executive Director, IR Conference Call Participants Olivia Brayer - Cantor Fitzgerald Olivia Brayer Joining us this morning at our Cantor Global Healthcare Conference. Really excited to have another year of it. My name is Olivia Brayer. I'm a senior Biotech Analyst here at Cantor. And we're really excited to have the Vertex IR team with u ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Cantor Global Healthcare Conference September 17, 2024 9:10 AM ET Company Participants Susie Lisa - SVP, IR Manisha Pai - Executive Director, IR Conference Call Participants Olivia Brayer - Cantor Fitzgerald Olivia Brayer Joining us this morning at our Cantor Global Healthcare Conference. Really excited to have another year of it. My name is Olivia Brayer. I'm a senior Biotech Analyst here at Cantor. And we're really excited to have the Vertex IR team with u ...

Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Shares of this drugmaker have returned +1.4% over the past month versus the Zacks S&P 500 composite's +4.9% change. The Zacks Medical - Biomedical and Genetics industry, to which Vertex belongs, has gained 3.7% over this period. Now the key question is: Where could the stock be headed in ...

Vertex Pharmaceuticals, Inc. (NASDAQ:VRTX) Morgan Stanley Conference Call September 5, 2024 11:30 AM ET Company Participants Reshma Kewalramani - President and CEO Charlie Wagner - CFO Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn Thanks for joining us, everybody. I'm Terence Flynn, the U.S. biopharma analyst here at Morgan Stanley. Before we get started, for important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclos ...

Vertex Pharmaceuticals has a lot going for it. Novo Nordisk (NVO 1.42%) is enjoying one of the best seasons in its history. Two of the company's drugs, Ozempic and Wegovy, have become household names. Novo's sales and profits are soaring. So is its share price, with the stock up around 150% over the last three years. Some investors who didn't buy Novo Nordisk earlier could be considering jumping on the bandwagon now. I have an alternate idea. Forget Novo Nordisk and buy another magnificent pharma stock inst ...

Vertex Pharmaceuticals Incorporated (VRTX) enjoys a dominant position in the cystic fibrosis (CF) market. In the first half of 2024, Vertex's CF revenues rose almost 10%, driven by the continued strong performance of Trikafta/Kaftrio, including in younger age groups. While in the near term, expansion to younger age groups should drive CF sales growth, the potential launch of Vertex's fifth CFTR modulator therapy, vanzacaftor triple combination, should drive growth in the medium term. While CF remains the ma ...

Vertex Pharmaceuticals Incorporated (VRTX) reported second-quarter 2024 results on Aug 1. Adjusted loss per share of $12.83 was wider than the Zacks Consensus Estimate of a loss of $11.50. The significant loss in the quarter was due to costs related to the $4.9 billion acquisition of Alpine Immune Sciences closed in May. Revenues of $2.65 billion were in line with the Zacks Consensus Estimate. Total revenues rose 6% year over year, primarily driven by higher sales of its cystic fibrosis (CF) drug Trikafta/K ...

Vertex Pharmaceuticals (VRTX) reported $2.65 billion in revenue for the quarter ended June 2024, representing a year-over-year increase of 6.1%. EPS of -$12.83 for the same period compares to $3.89 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $2.65 billion, representing a surprise of -0.08%. The company delivered an EPS surprise of -11.57%, with the consensus EPS estimate being -$11.50. While investors scrutinize revenue and earnings changes year-over-year and how they compar ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ________________________________________________________ FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 000-19319 ____________________________________________ Vertex Pharmac ...

Vertex Pharmaceuticals Incorporated (VRTX) reported second-quarter 2024 adjusted loss per share of $12.83, which was wider than the Zacks Consensus Estimate of a loss of $11.50. In the year-ago quarter, Vertex recorded adjusted earnings of $3.89 per share. The significant loss in the quarter was due to costs related to the $4.9 billion acquisition of Alpine Immune Sciences, which was closed in May. The company reported total revenues of $2.65 billion, comprising cystic fibrosis (CF) product revenues. The fi ...